Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal

Tempus AI has agreed to get Personalis successful a $1.5bn banal woody positioned to fortify the company's oncology proviso with minimal residual illness (MRD) testing.

Under the deal, expected to adjacent by aboriginal 2027, Tempus volition get the cancer-tech firm's outstanding banal astatine $16.25 per share, equating to a acquisition terms of $1.5bn, discounting Tempus' existing 12.25% involvement successful the California-based company. The mooted stock terms offering represents a 6% premium connected Personalis' stock terms of $15.39 astatine marketplace adjacent connected 17 July, portion Tempus besides has the enactment to workout its close to wage up to 50% of the transaction successful cash.

Following the deal's announcement up of marketplace unfastened connected 20 July, Tempus' shares, listed connected the Nasdaq, fell by 7.74% from a marketplace unfastened of $49.78 to a $48.41 close. Tempus has a marketplace headdress of $8.69bn. Meanwhile, Personalis stock, besides listed connected the Nasdaq, fell 13.2% to a marketplace adjacent of $13.34. Personalis has a marketplace headdress of $1.4bn.

In a probe note, William Blair analysts said a unit constituent volition beryllium profitability fixed Personalis' loss-making position, indicating a imaginable root of capitalist hesitation connected the market. Tempus and Personalis person been collaborating since November 2023, a pair-up that saw the associated improvement and commercialisation of Personalis' NeXT Personal MRD test.

MRD testing, which is designed to observe hint amounts of crab cells remaining successful the assemblage pursuing crab attraction specified arsenic chemotherapy, is attracting rising involvement successful the precision oncology abstraction

Tempus CEO, Eric Lefkofsky, commented: "MRD is simply a ample and rapidly increasing marketplace with the imaginable to genuinely alteration however crab patients are monitored, helping clinicians marque faster and much informed decisions erstwhile crab recurs.

"Through our existing collaboration with Personalis, we person already demonstrated the spot of combining highly delicate MRD exertion with our commercialized infrastructure. With objective adoption and reimbursement momentum building, we are collectively good positioned to seizure this opportunity."

Personalis reported preliminary Q2 gross of $22.4m, with 10,384 MRD tests distributed passim the quarter, representing a 33% summation successful trial volumes connected a quarter-over-quarter basis. However, the institution is presently operating astatine a nett loss.

Chris Hall, CEO of Personalis, commented: "Combining with Tempus gives america the scale, complementary capabilities and resources to accelerate innovation and present adjacent greater worth to patients, clinicians and biopharma partners."